Literature DB >> 11135252

Quantitative analysis of immunogold labeling indicates low levels and non-vesicular localization of L-aspartate in rat primary afferent terminals.

M Larsson1, S Persson, O P Ottersen, J Broman.   

Abstract

The role of L-aspartate as an excitatory neurotransmitter in primary afferent synapses in the spinal cord dorsal horn is disputed. To further investigate this issue, we examined the presence of aspartate-like immunoreactivity in primary afferent nerve terminals and other tissue components of the dorsal horn. We also examined the relationship between aspartate and glutamate immunogold labeling density and the density of synaptic vesicles in primary afferent terminals and presumed inhibitory terminals forming symmetric synapses. Weak aspartate immunosignals, similar to or lower than those displayed by presumed inhibitory terminals, were detected in both C-fiber primary afferent terminals in lamina II (dense sinusoid axon terminals, identified by morphological criteria) and in A-fiber primary afferent terminals in laminae III-IV (identified with anterograde transport of choleragenoid-horseradish peroxidase conjugate). The aspartate immunogold signal in primary afferent terminals was only about one-fourth of that in deep dorsal horn neuronal cell bodies. Further, whereas significant positive correlations were evident between synaptic vesicle density and glutamate immunogold labeling density in both A- and C-fiber primary afferent terminals, none of the examined terminal populations displayed a significant correlation between synaptic vesicle density and aspartate immunogold labeling density. Thus, our results indicate relatively low levels and a non-vesicular localization of aspartate in primary afferent terminals. It is therefore suggested that aspartate, rather than being a primary afferent neurotransmitter, serves a role in the intermediary metabolism in primary afferent terminals. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11135252     DOI: 10.1002/1096-9861(20010205)430:2<147::aid-cne1021>3.0.co;2-5

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  8 in total

1.  Retrogradely transported fluorogold accumulates in lysosomes of neurons and is detectable ultrastructurally using post-embedding immuno-gold methods.

Authors:  Stefan Persson; Leif A Havton
Journal:  J Neurosci Methods       Date:  2009-07-23       Impact factor: 2.390

Review 2.  Ionotropic glutamate receptors in spinal nociceptive processing.

Authors:  Max Larsson
Journal:  Mol Neurobiol       Date:  2009-10-31       Impact factor: 5.590

Review 3.  Aspartate release and signalling in the hippocampus.

Authors:  J Victor Nadler
Journal:  Neurochem Res       Date:  2010-10-16       Impact factor: 3.996

4.  Translocation of GluR1-containing AMPA receptors to a spinal nociceptive synapse during acute noxious stimulation.

Authors:  Max Larsson; Jonas Broman
Journal:  J Neurosci       Date:  2008-07-09       Impact factor: 6.167

5.  Glutamate, but not aspartate, is enriched in trigeminothalamic tract terminals and associated with their synaptic vesicles in the rat nucleus submedius.

Authors:  Stefan Persson; Jonas Broman
Journal:  Exp Brain Res       Date:  2004-02-17       Impact factor: 1.972

Review 6.  Tetanus: pathophysiology, treatment, and the possibility of using botulinum toxin against tetanus-induced rigidity and spasms.

Authors:  Bjørnar Hassel
Journal:  Toxins (Basel)       Date:  2013-01-08       Impact factor: 4.546

7.  Synaptic Organization of VGLUT3 Expressing Low-Threshold Mechanosensitive C Fiber Terminals in the Rodent Spinal Cord.

Authors:  Max Larsson; Jonas Broman
Journal:  eNeuro       Date:  2019-02-14

8.  VGluT1 Deficiency Impairs Visual Attention and Reduces the Dynamic Range of Short-Term Plasticity at Corticothalamic Synapses.

Authors:  Sarah H Lindström; Sofie C Sundberg; Max Larsson; Fredrik K Andersson; Jonas Broman; Björn Granseth
Journal:  Cereb Cortex       Date:  2020-03-14       Impact factor: 5.357

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.